Loading...
•
Mar 31, 2021
PMV Pharma Q1 2021 Earnings Report
Reported financial results for Q1 2021 and provided corporate highlights.
Key Takeaways
PMV Pharma reported a net loss of $11.6 million for the quarter ended March 31, 2021. The company ended the quarter with $348.4 million in cash, cash equivalents, and marketable securities. Enrollment in the Phase 1/2 trial of PC14586 is progressing as planned.
Presented preclinical data on PC14586 at the American Association for Cancer Research Annual Meeting 2021.
Continued to enroll patients in the Phase 1 portion of a Phase 1/2 clinical trial of PC14586.
Expanded Board of Directors with the appointment of Charles M. Baum, M.D., Ph.D.
Expanded Scientific Advisory Board with the appointment of Guillermina (Gigi) Lozano, Ph.D.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...